Nicola De Stefano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7310892/publications.pdf

Version: 2024-02-01

250	32,304	9786 73	4548 171
papers	citations	h-index	g-index

254	254	254	28150
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple Sclerosis Journal, 2022, 28, 111-120.	3.0	15
2	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. Multiple Sclerosis Journal, 2022, 28, 154-159.	3.0	3
3	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. Multiple Sclerosis Journal, 2022, 28, 885-899.	3.0	3
4	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. Molecular Psychiatry, 2022, 27, 1010-1019.	7.9	10
5	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
6	A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging. Investigative Radiology, 2022, 57, 423-432.	6.2	18
7	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. NeuroImage: Clinical, 2022, 34, 102972.	2.7	11
8	Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 787160.	2.4	9
9	Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability. European Journal of Neurology, 2022, 29, 2036-2046.	3.3	6
10	Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon betaâ€1a. European Journal of Neurology, 2022, 29, 2024-2035.	3.3	6
11	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine, 2022, 80, 104042.	6.1	54
12	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. NeuroImage: Clinical, 2022, 35, 103048.	2.7	17
13	B Lymphocytes in Alzheimerâ€™s Diseaseâ€”A Comprehensive Review. Journal of Alzheimer's Disease, 2022, 88, 1241-1262.	2.6	5
14	Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	15
15	Peak width of skeletonized mean diffusivity (PSMD) and cognitive functions in relapsing-remitting multiple sclerosis. Brain Imaging and Behavior, 2021, 15, 2228-2233.	2.1	6
16	Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. Multiple Sclerosis Journal, 2021, 27, 39-51.	3.0	21
17	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. NeuroImage: Clinical, 2021, 29, 102549.	2.7	20
18	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370

#	Article	IF	Citations
19	Dynamics of pseudoâ€atrophy in RRMS reveals predominant gray matter compartmentalization. Annals of Clinical and Translational Neurology, 2021, 8, 623-630.	3.7	14
20	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	9.0	30
21	MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. Multiple Sclerosis and Related Disorders, 2021, 49, 102790.	2.0	8
22	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurology, 2021, 78, 414.	9.0	86
23	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. Brain, 2021, 144, 1296-1311.	7.6	81
24	Structural and Functional Connectivity Substrates of Cognitive Impairment in Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 671894.	2.4	11
25	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
26	Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia. Neurological Sciences, 2021, 42, 5365-5368.	1.9	2
27	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	10.2	302
28	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine, 2021, 72, 103581.	6.1	184
29	MRI Prognostic Factors in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Antibody Disease. Frontiers in Neurology, 2021, 12, 679881.	2.4	9
30	Changes in grey matter volume and functional connectivity in cluster headache versus migraine. Brain Imaging and Behavior, 2020, 14, 496-504.	2.1	16
31	Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 476-488.	3.0	54
32	Response to Dr Boykoâ€™s letter: â€˜Radiologically isolated syndrome with oligoclonal bands in CSF (RISâ€‰+â€‰OCB) can be classified as highly MS-risk groupâ€™. Multiple Sclerosis Journal, 2020, 26, 871-871.	3.0	0
33	Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 585296.	2.4	4
34	The IN-DEEP project â€œINtegrating and Deriving Evidence, Experiencesâ€: a web information model on magnetic resonance imaging for people with multiple sclerosis. Journal of Neurology, 2020, 267, 2421-2431.	3.6	1
35	Combining biomarkers to profile multiple sclerosis patients. Nature Reviews Neurology, 2020, 16, 463-464.	10.1	5
36	Altered Large-Scale Brain Functional Connectivity in Ocular Hypertension. Frontiers in Neuroscience, 2020, 14, 146.	2.8	10

#	Article	IF	Citations
37	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. Journal of Neurology, 2020, 267, 3541-3554.	3.6	14
38	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	10.1	150
39	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. Annals of Neurology, 2020, 88, 93-105.	5.3	79
40	Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome. European Journal of Neurology, 2019, 26, 162-167.	3.3	21
41	DTI-derived indexes of brain WM correlate with cognitive performance in vascular MCI and small-vessel disease. A TBSS study. Brain Imaging and Behavior, 2019, 13, 594-602.	2.1	16
42	MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis. Journal of Neurology, 2019, 266, 2848-2858.	3.6	16
43	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurology, 2019, 76, 1446.	9.0	119
44	Automated lesion segmentation with BIANCA: Impact of population-level features, classification algorithm and locally adaptive thresholding. NeuroImage, 2019, 202, 116056.	4.2	32
45	Exploring the role of music therapy in multiple sclerosis: brief updates from research to clinical practice. Neurological Sciences, 2019, 40, 2277-2285.	1.9	15
46	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. NeuroImage: Clinical, 2019, 24, 102011.	2.7	42
47	Fractal dimension of cerebral white matter: A consistent feature for prediction of the cognitive performance in patients with small vessel disease and mild cognitive impairment. NeuroImage: Clinical, 2019, 24, 101990.	2.7	30
48	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
49	Lifespan normative data on rates of brain volume changes. Neurobiology of Aging, 2019, 81, 30-37.	3.1	40
50	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain, 2019, 142, 1858-1875.	7.6	303
51	How much do periventricular lesions assist in distinguishing migraine with aura from CIS?. Neurology, 2019, 92, e1739-e1744.	1.1	15
52	Relevance of brain lesion location for cognition in vascular mild cognitive impairment. NeuroImage: Clinical, 2019, 22, 101789.	2.7	12
53	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.1	88
54	Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 294-297.	2.0	19

#	Article	IF	Citations
55	Learning ability correlates with brain atrophy and disability progression in RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 38-43.	1.9	18
56	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 541-553.	3.0	32
57	Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. Multiple Sclerosis Journal, 2019, 25, 217-223.	3.0	5
58	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nature Reviews Neurology, 2018, 14, 199-213.	10.1	157
59	Application of the DSM-5 Criteria for Major Neurocognitive Disorder to Vascular MCI Patients. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 104-116.	1.3	13
60	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Multiple Sclerosis Journal, 2018, 24, 214-221.	3.0	77
61	Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSLâ€”a longitudinal brain volumetry study in healthy adults. Neurobiology of Aging, 2018, 65, 1-6.	3.1	25
62	Deep gray matter volume loss drives disability worsening in multiple sclerosis. Annals of Neurology, 2018, 83, 210-222.	5.3	295
63	Response to â€˜Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?â€™ by Schiffmann et al.. Multiple Sclerosis Journal, 2018, 24, 1388-1389.	3.0	1
64	Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Radiology, 2018, 288, 554-564.	7.3	47
65	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. NeuroImage: Clinical, 2018, 19, 466-475.	2.7	47
66	Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL. Journal of Neurology, 2018, 265, 1158-1165.	3.6	18
67	Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis Journal, 2018, 24, 222-226.	3.0	47
68	Diffuse brain damage in normal tension glaucoma. Human Brain Mapping, 2018, 39, 532-541.	3.6	64
69	Effective Utilization of MRIÂin the Diagnosis and Management of Multiple Sclerosis. Neurologic Clinics, 2018, 36, 27-34.	1.8	27
70	SIENAâ€XL for improving the assessment of gray and white matter volume changes on brain MRI. Human Brain Mapping, 2018, 39, 1063-1077.	3.6	20
71	The hippocampus in multiple sclerosis. Lancet Neurology, The, 2018, 17, 918-926.	10.2	90
72	Progression of regional grey matter atrophy in multiple sclerosis. Brain, 2018, 141, 1665-1677.	7.6	269

#	Article	IF	Citations
73	The dilemma of benign multiple sclerosis: Can we predict the risk of losing the â€œbenign statusâ€? A 12-year follow-up study. Multiple Sclerosis and Related Disorders, 2018, 26, 71-73.	2.0	6
74	Subcutaneous interferon Î²-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 285-294.	1.9	38
75	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Medicine, 2017, 15, 41.	5.5	212
76	The role of dentate nuclei in human oculomotor control: insights from cerebrotendinous xanthomatosis. Journal of Physiology, 2017, 595, 3607-3620.	2.9	16
77	Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. CNS Drugs, 2017, 31, 289-305.	5.9	55
78	Vitamin D levels in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Neurological Sciences, 2017, 38, 1333-1336.	1.9	3
79	The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. Journal of Neurology, 2017, 264, 862-874.	3.6	43
80	¹¹C-PBR28 and ¹⁸F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. Journal of Nuclear Medicine, 2017, 58, 1477-1482.	5.0	57
81	Resting state fMRI regional homogeneity correlates with cognition measures in subcortical vascular cognitive impairment. Journal of the Neurological Sciences, 2017, 373, 1-6.	0.6	36
82	Brain MRI atrophy quantification in MS. Neurology, 2017, 88, 403-413.	1.1	188
83	Imaging outcome measures for progressive multiple sclerosis trials. Multiple Sclerosis Journal, 2017, 23, 1614-1626.	3.0	62
84	Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials â€“ Commentary. Multiple Sclerosis Journal, 2017, 23, 1458-1460.	3.0	2
85	Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e379.	6.0	15
86	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. Multiple Sclerosis Journal, 2017, 23, 656-664.	3.0	34
87	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Frontiers in Neurology, 2017, 8, 608.	2.4	19
88	Functional Evaluation of Awareness in Vegetative and Minimally Conscious State. Open Neuroimaging Journal, 2017, 11, 17-25.	0.2	17
89	Granular cell tumor of the orbit: pathological features and treatment. Journal of Neurosurgical Sciences, 2017, 61, 342-343.	0.6	2
90	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309903.	1.9	162

#	Article	IF	Citations
91	Unusual case of traumatic neuroma of the orbit. Orbit, 2016, 35, 62-65.	0.8	5
92	MRI monitoring of spinal cord changes in patients with multiple sclerosis. Current Opinion in Neurology, 2016, 29, 445-452.	3.6	5
93	Relationship of white and gray matter abnormalities to clinical and genetic features in myotonic dystrophy type 1. NeuroImage: Clinical, 2016, 11, 678-685.	2.7	55
94	Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2016, 7, 98-101.	2.0	23
95	Advanced Structural and Functional Brain MRI in Multiple Sclerosis. Seminars in Neurology, 2016, 36, 163-176.	1.4	26
96	Early changes of brain connectivity in primary open angle glaucoma. Human Brain Mapping, 2016, 37, 4581-4596.	3.6	76
97	A practical review of the neuropathology and neuroimaging of multiple sclerosis. Practical Neurology, 2016, 16, 279-287.	1.1	30
98	Primary <scp>P</scp>rogressive <scp>M</scp>ultiple <scp>S</scp>clerosis <scp>E</scp>volving <scp>F</scp>rom <scp>R</scp>adiologically <scp>I</scp>solated <scp>S</scp>yndrome. Annals of Neurology, 2016, 79, 288-294.	5.3	130
99	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.1	98
100	Structural <scp>MRI</scp> correlates of cognitive impairment in patients with multiple sclerosis. Human Brain Mapping, 2016, 37, 1627-1644.	3.6	99
101	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology, The, 2016, 15, 292-303.	10.2	679
102	Optimizing treatment success in multiple sclerosis. Journal of Neurology, 2016, 263, 1053-1065.	3.6	155
103	Inclusion of brain volume loss in a revised measure of â€˜no evidence of disease activityâ€™ (NEDA-4) in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1297-1305.	3.0	228
104	APOE É›2 is associated with white matter hyperintensity volume in CADASIL. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 199-203.	4.3	28
105	Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. , 2016, 12, 407-418.		34
106	Alterations in Functional and Structural Connectivity in Pediatric-Onset Multiple Sclerosis. PLoS ONE, 2016, 11, e0145906.	2.5	28
107	A human post-mortem brain model for the standardization of multi-centre MRI studies. NeuroImage, 2015, 110, 11-21.	4.2	30
108	Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurology, The, 2015, 14, 302-317.	10.2	437

#	Article	IF	Citations
109	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€"clinical implementation in the diagnostic process. Nature Reviews Neurology, 2015, 11, 471-482.	10.1	354
110	Optimizing therapy early in multiple sclerosis: An evidence-based view. Multiple Sclerosis and Related Disorders, 2015, 4, 460-469.	2.0	83
111	Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 675-676.	3.0	64
112	Connectivityâ€based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. Human Brain Mapping, 2015, 36, 2809-2825.	3.6	69
113	Appraisal of Brain Connectivity in Radiologically Isolated Syndrome by Modeling Imaging Measures. Journal of Neuroscience, 2015, 35, 550-558.	3.6	42
114	Long-term assessment of no evidence of disease activity in relapsing-remitting MS. Neurology, 2015, 85, 1722-1723.	1.1	26
115	GABA: a new imaging biomarker of neurodegeneration in multiple sclerosis?. Brain, 2015, 138, 2467-2468.	7.6	7
116	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nature Reviews Neurology, 2015, 11, 676-686.	10.1	109
117	Prognostic biomarkers of IFNb therapy in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 894-904.	3.0	20
118	Structural and Functional Brain Changes beyond Visual System in Patients with Advanced Glaucoma. PLoS ONE, 2014, 9, e105931.	2.5	91
119	Spinal cord imaging in multiple sclerosis. Neurology, 2014, 83, 1306-1307.	1.1	2
120	Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: Yes. Multiple Sclerosis Journal, 2014, 20, 537-538.	3.0	8
121	Efficacy of subcutaneous interferon Â-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 647-653.	1.9	23
122	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 851-858.	1.9	101
123	The burden of microstructural damage modulates cortical activation in elderly subjects with MCI and leukoâ€araiosis. A DTI and fMRI study. Human Brain Mapping, 2014, 35, 819-830.	3.6	48
124	Effects of Sapropterin on Endothelium-Dependent Vasodilation in Patients With CADASIL. Stroke, 2014, 45, 2959-2966.	2.0	16
125	Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Annals of Neurology, 2014, 75, 43-49.	5.3	240
126	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders, 2014, 3, 147-155.	2.0	57

#	Article	IF	Citations
127	Patient subgroup analyses of the treatment effect of subcutaneous interferon Î²-1a on development of multiple sclerosis in the randomized controlled REFLEX study. Journal of Neurology, 2014, 261, 490-499.	3.6	13
128	MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes. Multiple Sclerosis Journal, 2014, 20, 280-281.	3.0	5
129	Twelve-year monitoring of a patient with megalencephalic leukoencephalopathy with subcortical cysts. Neurological Sciences, 2014, 35, 1249-53.	1.9	1
130	Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. CNS Drugs, 2014, 28, 147-156.	5.9	254
131	A novel approach with â€œskeletonised MTRâ€•measures tractâ€specific microstructural changes in early primaryâ€progressive MS. Human Brain Mapping, 2014, 35, 723-733.	3.6	12
132	Multiple Sclerosis and Inflammatory Diseases. , 2014, , 162-171.		0
133	Automated identification of brain new lesions in multiple sclerosis using subtraction images. Journal of Magnetic Resonance Imaging, 2014, 39, 1543-1549.	3.4	45
134	Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 214-219.	3.0	51
135	Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. Lancet Neurology, The, 2014, 13, 807-822.	10.2	197
136	Genome-Wide Genotyping Demonstrates a Polygenic Risk Score Associated With White Matter Hyperintensity Volume in CADASIL. Stroke, 2014, 45, 968-972.	2.0	33
137	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. PLoS ONE, 2014, 9, e90509.	2.5	254
138	Defining and scoring response to IFN-Î² in multiple sclerosis. Nature Reviews Neurology, 2013, 9, 504-512.	10.1	101
139	Clinical Course of Two Italian Siblings with Ataxia-Telangiectasia-Like Disorder. Cerebellum, 2013, 12, 596-599.	2.5	20
140	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	1.9	46
141	Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Multiple Sclerosis Journal, 2013, 19, 411-417.	3.0	23
142	Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1082-1091.	1.9	267
143	The radiologically isolated syndrome dilemma: just an incidental radiological finding or presymptomatic multiple sclerosis?. Multiple Sclerosis Journal, 2013, 19, 257-258.	3.0	8
144	Clinical use of brain volumetry. Journal of Magnetic Resonance Imaging, 2013, 37, 1-14.	3.4	100

#	Article	IF	Citations
145	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology, 2013, 80, 234-241.	1.1	53
146	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology, 2013, 80, 2090-2094.	1.1	63
147	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology, 2013, 80, 1330-1337.	1.1	189
148	Cognitive reserve and cortical atrophy in multiple sclerosis. Neurology, 2013, 80, 1728-1733.	1.1	113
149	Impaired vasoreactivity in mildly disabled CADASIL patients. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 268-274.	1.9	18
150	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews Neurology, 2012, 8, 13-21.	10.1	67
151	Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology, 2012, 78, 309-314.	1.1	169
152	Modelling the distribution of cortical lesions in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 229-231.	3.0	11
153	The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale. Stroke, 2012, 43, 2871-2876.	2.0	68
154	Efficacy and safety of subcutaneous interferon beta-1a in relapsingâ€“remitting multiple sclerosis: Further outcomes from the IMPROVE study. Journal of the Neurological Sciences, 2012, 312, 97-101.	0.6	31
155	Risk and Determinants of Dementia in Patients with Mild Cognitive Impairment and Brain Subcortical Vascular Changes: A Study of Clinical, Neuroimaging, and Biological Markersâ€”The VMCI-Tuscany Study: Rationale, Design, and Methodology. International Journal of Alzheimer's Disease, 2012, 2012, 1-7.	2.0	26
156	Neurodegeneration in friedreich's ataxia is associated with a mixed activation pattern of the brain. A fMRI study. Human Brain Mapping, 2012, 33, 1780-1791.	3.6	33
157	Evaluating and reducing the impact of white matter lesions on brain volume measurements. Human Brain Mapping, 2012, 33, 2062-2071.	3.6	280
158	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology, The, 2012, 11, 33-41.	10.2	185
159	Association between pathological and MRI findings in multiple sclerosis. Lancet Neurology, The, 2012, 11, 349-360.	10.2	356
160	Evidence of diffuse damage in frontal and occipital cortex in the brain of patients with post-traumatic stress disorder. Neurological Sciences, 2012, 33, 59-68.	1.9	51
161	Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis. PLoS ONE, 2012, 7, e44826.	2.5	78
162	Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 541-549.	3.0	52

#	Article	IF	Citations
163	Modeling the Distribution of New MRI Cortical Lesions in Multiple Sclerosis Longitudinal Studies. PLoS ONE, 2011, 6, e26712.	2.5	13
164	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. European Journal of Neuroscience, 2011, 33, 1256-1263.	2.6	25
165	Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI. Journal of Neurology, 2011, 258, 2240-2247.	3.6	19
166	1H-MR Spectroscopy in Traumatic Brain Injury. Neurocritical Care, 2011, 14, 127-133.	2.4	55
167	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. Multiple Sclerosis Journal, 2011, 17, 319-326.	3.0	11
168	Magnetic Resonance Techniques in Multiple Sclerosis. Archives of Neurology, 2011, 68, 1514.	4.5	120
169	Retinal Nerve Fiber Layer Thinning in CADASIL: An Optical Coherence Tomography and MRI Study. Cerebrovascular Diseases, 2011, 31, 77-82.	1.7	25
170	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. PLoS ONE, 2011, 6, e19452.	2.5	74
171	Cognition in multiple sclerosis: relevance of lesions, brain atrophy and proton MR spectroscopy. Neurological Sciences, 2010, 31, 245-248.	1.9	44
172	MRâ€compatible device for monitoring hand tracing and writing tasks in fMRI with an application to healthy subjects. Concepts in Magnetic Resonance Part A: Bridging Education and Research, 2010, 36A, 139-152.	0.5	10
173	Intercenter differences in diffusion tensor MRI acquisition. Journal of Magnetic Resonance Imaging, 2010, 31, 1458-1468.	3.4	81
174	Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1326-1334.	3.0	30
175	Assessing Neuronal Metabolism In Vivo by Modeling Imaging Measures. Journal of Neuroscience, 2010, 30, 15030-15033.	3.6	47
176	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology, 2010, 74, 1868-1876.	1.1	284
177	Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Multiple Sclerosis Journal, 2010, 16, 1474-1482.	3.0	157
178	Age-related changes in grey and white matter structure throughout adulthood. NeuroImage, 2010, 51, 943-951.	4.2	428
179	Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 888-892.	3.0	31
180	APOE-Îµ4 is not associated with cognitive impairment in relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 1489-1494.	3.0	21

#	Article	IF	Citations
181	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. Human Brain Mapping, 2009, 30, 2412-2425.	3.6	51
182	Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 55-60.	0.6	66
183	Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. Journal of the Neurological Sciences, 2009, 284, 223.	0.6	4
184	Response to the letter â€œProgression of gray matter atrophy and its association with white matter lesions in relapsingâ€“remitting multiple sclerosisâ€•by Bendfeldt et al.. Journal of the Neurological Sciences, 2009, 285, 269.	0.6	0
185	Introduction to MR spectroscopy in vivo. , 2009, , 1-18.		0
186	Basic concepts of advanced MRI techniques. Neurological Sciences, 2008, 29, 290-295.	1.9	31
187	Leukoencephalopathies and metabolic diseases. Neurological Sciences, 2008, 29, 323-326.	1.9	2
188	Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. Journal of Neurology, 2008, 255, 581-586.	3.6	116
189	Adult polyglucosan body disease: Proton magnetic resonance spectroscopy of the brain and novel mutation in the GBE1 gene. Muscle and Nerve, 2008, 37, 530-536.	2.2	27
190	Short-term combination of glatiramer acetate with IV steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2008, 266, 44-50.	0.6	11
191	Enhanced brain extraction improves the accuracy of brain atrophy estimation. NeuroImage, 2008, 40, 583-589.	4.2	58
192	A case of ovarioleukodystrophy without eIF2B mutations. Journal of the Neurological Sciences, 2008, 268, 183-186.	0.6	5
193	Brain Atrophy Assessment in Multiple Sclerosis: Importance and Limitations. Neuroimaging Clinics of North America, 2008, 18, 675-686.	1.0	68
194	Voxel-Based Assessment of Differences in Damage and Distribution of White Matter Lesions Between Patients With Primary Progressive and Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2008, 65, 236-43.	4.5	38
195	Plasma Levels of Asymmetric Dimethylarginine in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarct and Leukoencephalopathy. Cerebrovascular Diseases, 2008, 26, 636-640.	1.7	27
196	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 455-464.	3.0	58
197	Right-to-Left Shunt in CADASIL Patients. Stroke, 2008, 39, 2155-2157.	2.0	34
198	Cardiac Autonomic Nervous System and Risk of Arrhythmias in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL). Stroke, 2007, 38, 276-280.	2.0	26

#	Article	IF	Citations
199	Detection of Cortical Inflammatory Lesions by Double Inversion Recovery Magnetic Resonance Imaging in Patients With Multiple Sclerosis. Archives of Neurology, 2007, 64, 1416.	4.5	282
200	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2007, 64, 1157.	4.5	203
201	Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: Cross-validation of BSI, SIENA and SIENAX. NeuroImage, 2007, 36, 1200-1206.	4.2	100
202	Self-paced frequency of a simple motor task and brain activation. NeuroImage, 2007, 38, 402-412.	4.2	24
203	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manuallyâ€edited SIENA and SIENAX. Journal of Magnetic Resonance Imaging, 2007, 26, 881-885.	3.4	45
204	Measuring Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2007, 17, 10S-15S.	2.0	51
205	MR Spectroscopy in Multiple Sclerosis. Journal of Neuroimaging, 2007, 17, 31S-35S.	2.0	84
206	Proton Magnetic Resonance Spectroscopy in Brain Metabolic Disorders. Klinische Neuroradiologie, 2007, 17, 223-229.	0.9	4
207	Neocortical volume decrease in relapsingâ€“remitting multiple sclerosis with mild cognitive impairment. Journal of the Neurological Sciences, 2006, 245, 195-199.	0.6	30
208	Diffuse metabolic changes in the brain of patients with familial amyloid polyneuropathy. A proton MRSI study. Journal of the Neurological Sciences, 2006, 246, 31-35.	0.6	4
209	Diffuse structural and metabolic brain changes in Fabry disease. Journal of Neurology, 2006, 253, 434-440.	3.6	23
210	Cortical damage in brains of patients with adult-form of myotonic dystrophy type 1 and no or minimal MRI abnormalities. Journal of Neurology, 2006, 253, 1471-1477.	3.6	27
211	MRI and the diagnosis of multiple sclerosis: expanding the concept of â€œno better explanationâ€. Lancet Neurology, The, 2006, 5, 841-852.	10.2	217
212	Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Annals of Neurology, 2006, 59, 634-639.	5.3	69
213	Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain, 2006, 129, 2008-2016.	7.6	75
214	Manifestations of early brain recovery associated with abstinence from alcoholism. Brain, 2006, 130, 36-47.	7.6	169
215	Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 501-507.	1.9	85
216	Non-progressive leukoencephalopathy with bilateral anterior temporal cysts: a case report and review of the literature. Brain and Development, 2005, 27, 73-77.	1.1	12

#	Article	IF	Citations
217	Peripheral neuropathy in CADASIL. Journal of Neurology, 2005, 252, 1206-1209.	3.6	23
218	Systemic Blood Pressure Profile in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke, 2005, 36, 2554-2558.	2.0	37
219	Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. Journal of the Neurological Sciences, 2005, 233, 203-208.	0.6	69
220	Hemodynamic Evaluation of the Optic Nerve Head in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Archives of Neurology, 2004, 61, 1230-3.	4.5	16
221	Brain mitochondrial impairment in ethylmalonic encephalopathy. Journal of Neurology, 2004, 251, 755-6.	3.6	10
222	Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage, 2004, 23, S208-S219.	4.2	11,375
223	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2004, 364, 1489-1496.	13.7	246
224	The Relationship Between Diffuse Axonal Damage and Fatigue in Multiple Sclerosis. Archives of Neurology, 2004, 61, 201.	4.5	181
225	A Novel NOTCH3 Frameshift Deletion and Mitochondrial Abnormalities in a Patient With CADASIL. Archives of Neurology, 2004, 61, 942.	4.5	52
226	Acute Unilateral Visual Loss as the First Symptom of Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Archives of Neurology, 2004, 61, 577.	4.5	42
227	Influence of Apolipoprotein E Ïµ4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2004, 61, 536.	4.5	45
228	MR evidence of structural and metabolic changes in brains of patients with Werner?s syndrome. Journal of Neurology, 2003, 250, 1169-1173.	3.6	13
229	Age-related Changes in Conventional, Magnetization Transfer, and Diffusion-Tensor MR Imaging Findings: Study with Whole-Brain Tissue Histogram Analysis1ÂÂ. Radiology, 2003, 227, 731-738.	7.3	134
230	Quantification of brain damage in cerebrotendinous xanthomatosis with magnetization transfer MR imaging. American Journal of Neuroradiology, 2003, 24, 495-500.	2.4	15
231	Diffuse Axonal and Tissue Injury in Patients With Multiple Sclerosis With Low Cerebral Lesion Load and No Disability. Archives of Neurology, 2002, 59, 1565.	4.5	176
232	Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis. NeuroImage, 2002, 17, 479-489.	4.2	1,828
233	Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. Journal of Neurology, 2002, 249, 662-668.	3.6	102
234	MR correlates of cerebral atrophy in patients with multiple sclerosis. Journal of Neurology, 2002, 249, 1072-1077.	3.6	79

#	Article	IF	Citations
235	Normalized Accurate Measurement of Longitudinal Brain Change. Journal of Computer Assisted Tomography, 2001, 25, 466-475.	0.9	449
236	Axonal metabolic recovery in multiple sclerosis patients treated with interferon Î²-1b. Journal of Neurology, 2001, 248, 979-986.	3.6	171
237	Severe metabolic abnormalities in the white matter of patients with vacuolating megalencephalic leukoencephalopathy with subcortical cysts. A proton MR spectroscopic imaging study. Journal of Neurology, 2001, 248, 403-409.	3.6	42
238	N-acetylaspartate: Usefulness as an indicator of viable neuronal tissue. Annals of Neurology, 2001, 50, 823-823.	5.3	35
239	Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain, 2001, 124, 121-131.	7.6	122
240	Evidence of Axonal Damage in the Early Stages of Multiple Sclerosis and Its Relevance to Disability. Archives of Neurology, 2001, 58, 65-70.	4.5	439
241	Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree. Annals of Neurology, 2000, 47, 179-185.	5.3	125
242	Multiple Sclerosis: Magnetization Transfer MR Imaging of White Matter before Lesion Appearance on T2-weighted Images. Radiology, 2000, 215, 824-830.	7.3	174
243	In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain, 1999, 122, 1933-1939.	7.6	176
244	In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using1H magnetic resonance spectroscopic imaging. Annals of Neurology, 1998, 44, 273-278.	5.3	78
245	Intracellular phosphates in inclusion body myositis?A 31P magnetic resonance spectroscopy study. , 1998, 21, 1523-1525.		26
246	Chemical pathology of acute demyelinating lesions and its correlation with disability. Annals of Neurology, 1995, 38, 901-909.	5.3	288
247	Reversible decreases in Nâ€acetylaspartate after acute brain injury. Magnetic Resonance in Medicine, 1995, 34, 721-727.	3.0	453
248	MRS in brain tumors. , 0, , 61-90.		1
249	MRS in infectious, inflammatory, and demyelinating lesions. , 0, , 110-130.		0
250	MRS in cerebral metabolic disorders. , 0, , 180-211.		1